Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat
- 1 February 2006
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (10) , 2180-2187
- https://doi.org/10.1038/sj.npp.1301036
Abstract
The vasopressin 1b receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, are orally active non-peptidic compounds with anxiolytic- and antidepressant-like activities in animal models. Presently, SSR149415 and SSR125543 were evaluated in a differential reinforcement of low-rate 72 s (DRL-72 s) schedule, a procedure known to respond differentially to antidepressants and anxiolytics. Male Wistar rats were trained to lever-press for food reinforcement, but only lever-presses occurring after a 72 s delay were reinforced; otherwise, presses were not rewarded, and the timer was reset to 0 s. The selective serotonin reuptake inhibitor, fluoxetine, and the benzodiazepine anxiolytic, diazepam, were tested in parallel. SSR149415 (10–30 mg/kg, i.p.) and SSR125543 (30 mg/kg, i.p.) increased the percentage of responses emitted in the inter-response time (IRT) bin (49–96 s), which resulted in a greater number of reinforced presses. Both compounds shifted the frequency distribution of responses toward longer IRT durations, with a preservation of the bell shape of the IRT distribution curve. Fluoxetine (10 mg/kg, i.p.) had an effect on DRL-72 s similar to that of SSR149415 and SSR125543. By contrast, diazepam increased the number of responses in IRT bin (0–12 s), and the IRT distribution curve was shifted toward shorter IRT durations and flattened. In summary, these results show that SSR149415 and SSR125543 displayed antidepressant-like activity in a DRL-72 s schedule in rat, confirming their therapeutic potential for the treatment of pathological states induced by chronic frustration such as depression.Keywords
This publication has 47 references indexed in Scilit:
- Evidence that the Lateral Septum is Involved in the Antidepressant-Like Effects of the Vasopressin V1b Receptor Antagonist, SSR149415Neuropsychopharmacology, 2004
- Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Anxiolytic Properties of the Selective, Non-peptidergic CRF1 Antagonists, CP154,526 and DMP695 A Comparison to Other Classes of Anxiolytic AgentNeuropsychopharmacology, 2001
- Frustrative nonreward and pituitary–adrenal activity in squirrel monkeysPhysiology & Behavior, 2000
- Somatodendritic α2‐Adrenoceptors in the Locus Coeruleus Are Involved in the In Vivo Modulation of Cortical Noradrenaline Release by the Antidepressant DesipramineJournal of Neurochemistry, 1998
- Vasopressinergic Control of Pituitary Adrenocorticotropin Secretion Comes of AgeFrontiers in Neuroendocrinology, 1993
- Effects of corticotropin releasing factor, desipramine and haloperidol on a DRL schedule of reinforcementPharmacology Biochemistry and Behavior, 1989
- Brain and pituitary receptors for corticotropin releasing factor: Localization and differential regulation after adrenalectomyPeptides, 1984
- Corticotropin Releasing Factor (CRF): Immunocytochemical localization and Radioimmunoassay (RIA)Life Sciences, 1982
- Behavioral effects of benzodiazepines: A reviewBiobehavioral Reviews, 1977